Last reviewed · How we verify

Ganirelix - Delayed Puberty Ganirelix Visit

University of Utah · Phase 1 active Small molecule Quality 0/100

Ganirelix - Delayed Puberty Ganirelix Visit is a Small molecule drug developed by University of Utah. It is currently in Phase 1 development. Also known as: Ganirelix SQ, Ganirelix Acetate.

At a glance

Generic nameGanirelix - Delayed Puberty Ganirelix Visit
Also known asGanirelix SQ, Ganirelix Acetate
SponsorUniversity of Utah
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ganirelix - Delayed Puberty Ganirelix Visit

What is Ganirelix - Delayed Puberty Ganirelix Visit?

Ganirelix - Delayed Puberty Ganirelix Visit is a Small molecule drug developed by University of Utah.

Who makes Ganirelix - Delayed Puberty Ganirelix Visit?

Ganirelix - Delayed Puberty Ganirelix Visit is developed by University of Utah (see full University of Utah pipeline at /company/university-of-utah).

Is Ganirelix - Delayed Puberty Ganirelix Visit also known as anything else?

Ganirelix - Delayed Puberty Ganirelix Visit is also known as Ganirelix SQ, Ganirelix Acetate.

What development phase is Ganirelix - Delayed Puberty Ganirelix Visit in?

Ganirelix - Delayed Puberty Ganirelix Visit is in Phase 1.

Related